Selected research
Industry Research
Cyclosporine Drugs Industry Research Report 2026
Market perspective
The global Cyclosporine Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Cyclosporine Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Cyclosporine Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Cyclosporine Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Cyclosporine Drugs include Takeda Pharmaceutical, Sun Pharmaceuticals Industries, Novartis, Huadong Medicine, Otsuka Pharmaceutical, Apotex, Allergan, AbbVie and United Biotech, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Cyclosporine Drugs market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Cyclosporine Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cyclosporine Drugs Market by Company
Takeda Pharmaceutical
Sun Pharmaceuticals Industries
Novartis
Huadong Medicine
Otsuka Pharmaceutical
Apotex
Allergan
AbbVie
United Biotech
Teva Pharmaceuticals Industries
Santen Pharmaceuticals
Regenerx Biopharmaceuticals
Mckesson Medical Surgical
Mayne Pharma Group
Cyclosporine Drugs Segment by Type
Oral
Parenteral
Cyclosporine Drugs Segment by Application
Dry Eye
Rheumatoid Arthritis
Transplant Rejection Prophylaxis
Psoriasis
Autoimmune Myasthenia Gravis
Others
Cyclosporine Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cyclosporine Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cyclosporine Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cyclosporine Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Cyclosporine Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Parenteral
Applications
- Dry Eye
- Rheumatoid Arthritis
- Transplant Rejection Prophylaxis
- Psoriasis
- Autoimmune Myasthenia Gravis
- Others
Companies covered
- Takeda Pharmaceutical
- Sun Pharmaceuticals Industries
- Novartis
- Huadong Medicine
- Otsuka Pharmaceutical
- Apotex
- Allergan
- AbbVie
- United Biotech
- Teva Pharmaceuticals Industries
- Santen Pharmaceuticals
- Regenerx Biopharmaceuticals
- Mckesson Medical Surgical
- Mayne Pharma Group
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Cyclosporine Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Oral
- 2.2.3 Parenteral
- 2.3 Cyclosporine Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Dry Eye
- 2.3.3 Rheumatoid Arthritis
- 2.3.4 Transplant Rejection Prophylaxis
- 2.3.5 Psoriasis
- 2.3.6 Autoimmune Myasthenia Gravis
- 2.3.7 Others
- 2.4 Assumptions and Limitations
3 Cyclosporine Drugs Breakdown Data by Type
- 3.1 Global Cyclosporine Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Cyclosporine Drugs Forecasted Market Size by Type (2027-2032)
4 Cyclosporine Drugs Breakdown Data by Application
- 4.1 Global Cyclosporine Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Cyclosporine Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Cyclosporine Drugs Market Perspective (2021-2032)
- 5.2 Global Cyclosporine Drugs Growth Trends by Region
- 5.2.1 Global Cyclosporine Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Cyclosporine Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Cyclosporine Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Cyclosporine Drugs Market Dynamics
- 5.3.1 Cyclosporine Drugs Industry Trends
- 5.3.2 Cyclosporine Drugs Market Drivers
- 5.3.3 Cyclosporine Drugs Market Challenges
- 5.3.4 Cyclosporine Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Cyclosporine Drugs Players by Revenue
- 6.1.1 Global Top Cyclosporine Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Cyclosporine Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Cyclosporine Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Cyclosporine Drugs Head Office and Area Served
- 6.4 Global Cyclosporine Drugs Players, Product Type & Application
- 6.5 Global Cyclosporine Drugs Manufacturers Established Date
- 6.6 Global Cyclosporine Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Cyclosporine Drugs Market Size (2021-2032)
- 7.2 North America Cyclosporine Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Cyclosporine Drugs Market Size by Country (2021-2026)
- 7.4 North America Cyclosporine Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Cyclosporine Drugs Market Size (2021-2032)
- 8.2 Europe Cyclosporine Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Cyclosporine Drugs Market Size by Country (2021-2026)
- 8.4 Europe Cyclosporine Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Cyclosporine Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Cyclosporine Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Cyclosporine Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Cyclosporine Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Cyclosporine Drugs Market Size (2021-2032)
- 10.2 South America Cyclosporine Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Cyclosporine Drugs Market Size by Country (2021-2026)
- 10.4 South America Cyclosporine Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Cyclosporine Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Cyclosporine Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Cyclosporine Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Cyclosporine Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda Pharmaceutical
- 12.1.1 Takeda Pharmaceutical Company Information
- 12.1.2 Takeda Pharmaceutical Business Overview
- 12.1.3 Takeda Pharmaceutical Revenue in Cyclosporine Drugs Business (2021-2026)
- 12.1.4 Takeda Pharmaceutical Cyclosporine Drugs Product Portfolio
- 12.1.5 Takeda Pharmaceutical Recent Developments
- 12.2 Sun Pharmaceuticals Industries
- 12.2.1 Sun Pharmaceuticals Industries Company Information
- 12.2.2 Sun Pharmaceuticals Industries Business Overview
- 12.2.3 Sun Pharmaceuticals Industries Revenue in Cyclosporine Drugs Business (2021-2026)
- 12.2.4 Sun Pharmaceuticals Industries Cyclosporine Drugs Product Portfolio
- 12.2.5 Sun Pharmaceuticals Industries Recent Developments
- 12.3 Novartis
- 12.3.1 Novartis Company Information
- 12.3.2 Novartis Business Overview
- 12.3.3 Novartis Revenue in Cyclosporine Drugs Business (2021-2026)
- 12.3.4 Novartis Cyclosporine Drugs Product Portfolio
- 12.3.5 Novartis Recent Developments
- 12.4 Huadong Medicine
- 12.4.1 Huadong Medicine Company Information
- 12.4.2 Huadong Medicine Business Overview
- 12.4.3 Huadong Medicine Revenue in Cyclosporine Drugs Business (2021-2026)
- 12.4.4 Huadong Medicine Cyclosporine Drugs Product Portfolio
- 12.4.5 Huadong Medicine Recent Developments
- 12.5 Otsuka Pharmaceutical
- 12.5.1 Otsuka Pharmaceutical Company Information
- 12.5.2 Otsuka Pharmaceutical Business Overview
- 12.5.3 Otsuka Pharmaceutical Revenue in Cyclosporine Drugs Business (2021-2026)
- 12.5.4 Otsuka Pharmaceutical Cyclosporine Drugs Product Portfolio
- 12.5.5 Otsuka Pharmaceutical Recent Developments
- 12.6 Apotex
- 12.6.1 Apotex Company Information
- 12.6.2 Apotex Business Overview
- 12.6.3 Apotex Revenue in Cyclosporine Drugs Business (2021-2026)
- 12.6.4 Apotex Cyclosporine Drugs Product Portfolio
- 12.6.5 Apotex Recent Developments
- 12.7 Allergan
- 12.7.1 Allergan Company Information
- 12.7.2 Allergan Business Overview
- 12.7.3 Allergan Revenue in Cyclosporine Drugs Business (2021-2026)
- 12.7.4 Allergan Cyclosporine Drugs Product Portfolio
- 12.7.5 Allergan Recent Developments
- 12.8 AbbVie
- 12.8.1 AbbVie Company Information
- 12.8.2 AbbVie Business Overview
- 12.8.3 AbbVie Revenue in Cyclosporine Drugs Business (2021-2026)
- 12.8.4 AbbVie Cyclosporine Drugs Product Portfolio
- 12.8.5 AbbVie Recent Developments
- 12.9 United Biotech
- 12.9.1 United Biotech Company Information
- 12.9.2 United Biotech Business Overview
- 12.9.3 United Biotech Revenue in Cyclosporine Drugs Business (2021-2026)
- 12.9.4 United Biotech Cyclosporine Drugs Product Portfolio
- 12.9.5 United Biotech Recent Developments
- 12.10 Teva Pharmaceuticals Industries
- 12.10.1 Teva Pharmaceuticals Industries Company Information
- 12.10.2 Teva Pharmaceuticals Industries Business Overview
- 12.10.3 Teva Pharmaceuticals Industries Revenue in Cyclosporine Drugs Business (2021-2026)
- 12.10.4 Teva Pharmaceuticals Industries Cyclosporine Drugs Product Portfolio
- 12.10.5 Teva Pharmaceuticals Industries Recent Developments
- 12.11 Santen Pharmaceuticals
- 12.11.1 Santen Pharmaceuticals Company Information
- 12.11.2 Santen Pharmaceuticals Business Overview
- 12.11.3 Santen Pharmaceuticals Revenue in Cyclosporine Drugs Business (2021-2026)
- 12.11.4 Santen Pharmaceuticals Cyclosporine Drugs Product Portfolio
- 12.11.5 Santen Pharmaceuticals Recent Developments
- 12.12 Regenerx Biopharmaceuticals
- 12.12.1 Regenerx Biopharmaceuticals Company Information
- 12.12.2 Regenerx Biopharmaceuticals Business Overview
- 12.12.3 Regenerx Biopharmaceuticals Revenue in Cyclosporine Drugs Business (2021-2026)
- 12.12.4 Regenerx Biopharmaceuticals Cyclosporine Drugs Product Portfolio
- 12.12.5 Regenerx Biopharmaceuticals Recent Developments
- 12.13 Mckesson Medical Surgical
- 12.13.1 Mckesson Medical Surgical Company Information
- 12.13.2 Mckesson Medical Surgical Business Overview
- 12.13.3 Mckesson Medical Surgical Revenue in Cyclosporine Drugs Business (2021-2026)
- 12.13.4 Mckesson Medical Surgical Cyclosporine Drugs Product Portfolio
- 12.13.5 Mckesson Medical Surgical Recent Developments
- 12.14 Mayne Pharma Group
- 12.14.1 Mayne Pharma Group Company Information
- 12.14.2 Mayne Pharma Group Business Overview
- 12.14.3 Mayne Pharma Group Revenue in Cyclosporine Drugs Business (2021-2026)
- 12.14.4 Mayne Pharma Group Cyclosporine Drugs Product Portfolio
- 12.14.5 Mayne Pharma Group Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst